To address this general difficulty, as well as various difficulties specific to impacts of COVID-19, we describe the approach of using natural history studies for comparative effectiveness analysis used in rare disease drug approval applications. This article is divided in three parts: substantial evidence standards, virtual matched control methodology, and inappropriateness of existing methods such as propensity score methods.